

























































Syntheses of Acyclic and Macrocyclic Compounds Derived
from 9,9-Diethylfluorene (Part I)
Pierre Seidel and Monika Mazik*[a]
A series of new 9,9-diethylfluorenes consisting of three side-
arms each bearing a heterocyclic, bis(carboxymethyl)amino, bis
(carbamoylmethyl)amino, bis(ethoxycarbonylmethyl)amino or
an amino group were prepared on the basis of 2,4,7-tris
(bromomethyl)-9,9-diethylfluorene. Imidazolyl, benzimidazolyl,
pyrazolyl, pyrrolyl, 1,3-dioxoisoindolyl and pyridinium groups
were taken into account as heterocyclic units, attached to the
aromatic skeleton via   CH2  ,   CH2NHCH2  or   CH2N=CH 
linkers. In addition to the seventeen 2,4,7-trisubstituted 9,9-
diethylfluorenes, two macrocyclic compounds were prepared
on the basis of 2,7-bis(aminomethyl)-9,9-diethylfluorene. The
excellent yield of the macrocyclization reaction is worth a
special mention. Both the acyclic and the macrocyclic fluorene-
based compounds have, among other things, the potential to
act as artificial receptors for different substrates in analogy to
the known receptors consisting of a benzene or biphenyl core.
Introduction
Fluorene-based acyclic and macrocyclic molecules[1] as well as
polymers[2] have been reported to have the potential for
numerous applications ranging from organic transistors, solar
cells and organic light-emitting diodes to lasers. Compounds
featuring a fluorene moiety have been further recognized as
chemosensors for some cationic,[3a–c] anionic[3d] and neutral
substrates[4] as well as agents for cell imaging.[5] In addition,
fluorene derivatives have shown interesting biological activities,
including antibacterial,[6a] antiviral,[6b] anticancer[7] and some
others.[8] Due to the above mentioned manifold application
possibilities of fluorene-based compounds, the syntheses of
new representatives of this class of compounds and the
investigation of their chemical, physical and biological proper-
ties remain the subject of intensive research.
Recently we have described the syntheses and crystal
structures of halogenomethyl-substituted 9,9-diethylfluorenes
1–3 (Figure 1), which are not only valuable starting materials for
the preparation of various fluorene-based compounds, but also
interesting building blocks for the formation of different
supramolecular motifs in the crystalline state.[9] For example,
the crystal structure of the iodomethyl substituted derivative 3
is characterized by the presence of an unusual triangular I3
synthon consisting of two I···I contacts with type I geometry
and one I···I contact that corresponds to the polarization-
induced type II category. Regarding the synthetic applications
described in our previous work,[9] the efficient one-step syn-
thesis of 9,9-diethylfluorene-2,4,7-tricarbaldehyde (4) on the
basis of 2,4,7-tris(bromomethyl)-9,9-diethylfluorene (2), provid-
ing three-fold higher yield of 4 than the known three-step
reaction sequence, is worthy of particular mention.
In this paper we describe the application of compound 2 for
the syntheses of seventeen 9,9-diethylfluorenes consisting of
three side-arms each bearing a heterocyclic, bis(carboxymethyl)
amino, bis(carbamoylmethyl)amino, bis(ethoxycarbonylmethyl)
amino or an amino group (compounds 5–21; see Figure 2). The





yl and pyridinium groups, are linked to the fluorene skeleton by
  CH2  (compounds 5–12),   CH2NHCH2  (19 and 21) or
  CH2N=CH  units (18 and 20).
[a] P. Seidel, Prof. Dr. M. Mazik
Institut für Organische Chemie
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Figure 1. Structures of fluorene derivatives 1–4, the syntheses and crystal
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Furthermore, we report the synthesis of macrocyclic com-
pounds 24 and 25 (Figure 3) on the basis of 2,7-bis(aminometh-
yl)-9,9-diethylfluorene (23). The synthesis of the last mentioned
compound from the analogue bearing two 1,3-dioxo-1,3-
dihydro-2H-isoindol-2-yl groups (compound 22) is also consid-
ered in this work.
Figure 2. Structures of the 2,4,7-trisubstituted 9,9-diethylfluorenes 5–21.
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Both the acyclic and the macrocyclic fluorene-based com-
pounds have among other things the potential to act as
artificial receptors for different ionic and neutral substrates in
the analogy to the known receptors possessing a benzene[10–14]
or biphenyl[15] core. For example, some representatives of the
acyclic and macrocyclic compounds consisting of the central
benzene or biphenyl unit were found to be effective receptors
for such substrates as ammonium ions,[11] ion pairs[12] or
carbohydrates.[10,14]
Results and discussion
Syntheses of compounds 5–11
Imidazolyl, benzimidazolyl, pyrazolyl and pyrrolyl groups were
shown to be valuable building blocks of benzene- and
biphenyl-based compounds, which have been developed as
artificial receptors for carbohydrates[10c,f–j,14,15c] or ammonium
ions.[11a–e] In this context, these groups have been also
considered as subunits of fluorene-based derivatives 5–11 and
18–21.
9,9-Diethylfluorenes consisting of three side-arms each
bearing an imidazolyl (compound 5), a benzimidazolyl (com-
pounds 6 and 7) or a pyrazolyl group (compounds 8–11) were
prepared by the reaction of 2,4,7-tris(bromomethyl)-9,9-diethyl-
fluorene (2) with 1H-imidazole, 1H-benzimidazole, 2-bromo-1H-
benzimidazole, 3,5-dimethyl-1H-pyrazole, 4-bromo-1H-pyrazole,
4-bromo-3,5-dimethyl-1H-pyrazole or 4-iodo-3,5-dimethyl-1H-
pyrazole (see Scheme 1). Reaction conditions like temperature,
time and the used base were varied to obtain the highest yields
of the desired products.
Starting with the synthesis of the derivative 5 consisting of
side-arms bearing 1H-imidazol-1-yl groups, precursor 2 was
treated with 1H-imidazole in tetrahydrofuran at room temper-
ature in the presence of N,N-diisopropylethylamine as a base.
The progress of the reaction was monitored by thin layer
chromatography (TLC), indicating a complete conversion of the
starting material after 24 hours. The purification of the raw
product via column chromatography provided compound 5
with 43% yield. One factor responsible for this low yield is the
formation of cationic species by a substitution of the second
ring-nitrogen of the imidazole-moiety under the used reaction
conditions. The same reaction procedure was tested for the
synthesis of the analogue bearing 1H-benzimidazol-1-yl groups
(compound 6); however, remarkably large quantities of the 2,7-
disubstituted intermediate were detected even after three days
of reaction time. The low reaction rate is caused by the more
bulky nucleophilic reagent (1H-benzimidazole) in combination
with the steric interactions between the substituents in C-4 and
Scheme 1. Syntheses of the imidazolyl-, benzimidazolyl- and pyrazolyl-functionalized derivatives 5–11. Procedure A: THF, DIPEA, room temperature (24 h) or
reflux (8 h); Procedure B: THF, NaH, reflux (8 h); compound 11 was synthesized and purified under exclusion of light. Yields: 43% (A) and 80% (B) of 5; 36% (A)
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C-5 position of the fluorene ring, resulting from the close
proximity between the two positions (bay region).[16] It should
be noted that NOESY experiments of the synthesized 2,4,7-
trisubstituted derivatives clearly indicate a strong coupling
between the CH2-group at C-4 and the proton at C-5. Perform-
ing the above mentioned reaction under reflux conditions for
8 hours enabled the synthesis of the desired product 6, but
only with 36% yield. Additionally to the higher reaction
temperature, a stronger nucleophilicity of the substitution
reagent is crucial to overcome the steric hindrance at the bay
region, which can be easily achieved by using a strong base.
Consequently, compound 6 was synthesized via a slightly varied
route, including deprotonation of 1H-benzimidazole by sodium
hydride (60% dispersion in mineral oil). Carrying out this
reaction under reflux conditions for 8 hours was sufficient to
prevent an incomplete substitution and compound 6 could be
obtained with 87% yield. Applying the same procedure to the
synthesis of compounds 5 and 7 allowed their preparation with
80% and 94% yield, respectively. In the case of 5[17] stirring at
room temperature for 24 hours yielded a better result than
refluxing for 8 hours.
A similar observation as in the case of the synthesis of 6 was
made synthesizing 8 by treatment of 2 with 3,5-dimethyl-1H-
pyrazole in the presence of N,N-diisopropylethylamine. The 3,5-
dimethyl-1H-pyrazole was also found to be less favourable for a
substitution in the bay region of the fluorene, since refluxing
the reaction mixture for 8 hours gave only a small amount of
product 8, as observed by TLC analysis. Increasing the reaction
time to 16 hours accomplished 67% yield of 8, but yet there
were still disubstituted intermediates detectable. Consequently,
both the compound 8 as well as the other derivatives
containing pyrazolyl groups (compounds 9–11) were prepared
through refluxing the starting material 2 with the correspond-
ing pyrazole derivative in the presence of sodium hydride. After
8 hours reaction time and the purification via column chroma-
tography the desired compounds 8–11 could be obtained with
yields ranged from good to excellent (82% of 8, 77% of 9, 83%
of 10 and 97% of 11).
Syntheses of compounds 12–17
The fluorene derivative containing pyridinium groups (com-
pound 12; see Figure 2 and Scheme 2) was readily accessible by
refluxing the starting material 2 with pyridine in chloroform for
4 hours. As the transformation of all three bromomethyl units
ran efficiently, this reaction was also applied as an intermediate
step for purification purposes. This represents a particularly
Scheme 2. Syntheses of the compounds 12–17. Reagents and conditions: (a) CHCl3, 4 h, reflux, (92% of 12); (b) THF/MeCN, K2CO3, 8 h, reflux (88% of 13); (c)
7n NH3 in MeOH, 7 d, room temperature (71% of 14); (d) MeOH/THF, 1n aq. NaOH, 24 h, room temperature (51% of 15a); (e) MeOH, KOH, 8 h, 40 °C; (f) 2n
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valuable purification method, since in the case of some
reactions of compound 2 with various nucleophiles, a relatively
high purification effort was a remaining issue. Due to similar
retention factors, even small amounts of incompletely sub-
stituted derivatives made a clean isolation of some target
compounds somewhat troublesome. The successful application
of this purification method can be demonstrated, for example,
by the procedure used in the synthesis of compound 13.
Refluxing diethyl iminodiacetate and 2 in tetrahydrofuran/
acetonitrile in the presence of potassium carbonate for 8 hours
provided only 31% of the target compound 13 in pure form,
because the major part was still contaminated with small
amounts of the 2,7-disubstituted intermediate, even after an
elaborate chromatographic purification. Treating the raw prod-
uct with pyridine under reflux conditions transferred all
remaining intermediates into pyridinium bromide salts, which
can be easily separated from the product (see experimental
part). In this way, the yield of compound 13 was increased to
88%.
Compound 13 also represents a precursor for the syntheses
of further fluorene derivatives, such as 14 and 15a/b, contain-
ing carboxamide and carboxyl groups, respectively. The
ammonolysis of 13 in methanol at room temperature yielded
71% of 14 and the saponification of 13 with sodium hydroxide,
diluted in a mixture consisting of tetrahydrofuran, methanol
and water, provided the sodium salt 15a (51%). For the
synthesis of 15b the saponification of 13 with potassium
hydroxide in dry methanol[18] was used, followed by the
acidification with 2n HCl(aq.). It should be noted, that the
intermediate potassium salt has to be free of any traces of
alcohol before adding acidic solutions, since reesterification
already occurs at neutral pH. After several purification steps, the
product 15b was obtained as a white solid (72%).
In addition to fluorenes bearing halogenomethyl or formyl
groups, the aminomethyl-functionalized derivatives are useful
starting materials for a wide range of fluorene-based com-
pounds. The Gabriel synthesis represents a common method to
generate amino groups via a two-step procedure, starting with
the reaction of potassium phthalimide with the corresponding
bromomethyl derivative in dimethylsulfoxide. During the syn-
thesis of 16, significant amounts of the 4-formyl-substituted
derivative were formed via Kornblum oxidation,[19] making the
isolation of 16 complicated. Since this side reaction already
occurred in significant amounts at room temperature, the
contact time of compound 2 with the solvent was reduced to a
necessary minimum. The reaction procedure included the
heating of the suspension of potassium phthalimide in dimeth-
ylsulfoxide to the reaction temperature and afterwards the
addition of compound 2 in portions without dissolving before-
hand. After quenching and repeated washing with water, the
dried raw product was found to be already of acceptable purity.
Recrystallization from tetrahydrofuran/chloroform gave the
pure product 16 with 91% yield. The subsequent Ing-Manske
workup[20] yielded the 2,4,7-tris(aminomethyl)-9,9-diethylfluor-
ene (17) in good yield (84%) and without further purification
needs.
Syntheses of compounds 18–21
The condensation reactions of 2,4,7-tris(aminomethyl)-9,9-dieth-
ylfluorene (17) with 1H-imidazole-2-carbaldehyde and 1H-
pyrrole-2-carbaldehyde to the corresponding imine derivatives
18 and 20 (see Scheme 3) were executed under nitrogen
atmosphere in dry solvents. Compound 18 was synthesized by
reacting 17 with 1H-imidazol-2-carbaldehyde in methanol and a
catalytic amount of acetic acid. The raw product was purified by
repeated precipitation from diethylether, yielding 74% of 18.
Due to the problematic isolation of 18, the in situ reduction of
the imine was followed to obtain the corresponding amino-
functionalized derivative 19. To remove the water formed
during the condensation reaction, triethyl orthoformate instead
of acetic acid was added to the reaction mixture. After refluxing
for 4 hours and subsequent cooling, sodium borohydride was
added and the mixture stirred overnight at room temperature.
Remaining borate residues were hydrolysed and the obtained
raw product was purified by column chromatography, yielding
44% of 19. The main concern is the poor solubility of 19 in
organic solvents other than methanol or dimethylsulfoxide,
causing a significant loss during the aqueous work up, which
can hardly be circumvented.
The same procedures were used for the synthesis of
compounds 20 and 21 bearing 1H-pyrrol-2-yl groups and gave
these two products with 24% and 20% yield, respectively.
Syntheses of compounds 22–25
As already mentioned above, besides the acyclic 2,4,7-trisub-
stituted 9,9-diethylfluorenes, the fluorene-based macrocycles,
such as 25, have the potential to act as artificial receptors. In
order to determine the best conditions for the macrocyclization
reaction between 2,7-bis(aminomethyl)-9,9-diethylfluorene (23)
and an aromatic bis-aldehyde, the first reactions have been
carried out using the commercially available isophthalaldehyde.
It should be noted that different factors influence the develop-
ment of efficient syntheses of macrocyclic structures and such
factors as well as the problems associated with the macro-
cyclization process have been often discussed in the
literature.[21] The development of methods for the synthesis of
various cyclophane tetraamines has been the subject of
research for years and many interesting results have been
published (for examples, see ref. [22]).
2,7-Bis(aminomethyl)-9,9-diethylfluorene (23) was prepared
from 26[23] via a Gabriel synthesis, including the preparation of
the derivative 22 (67% yield, see Scheme 4) and its subsequent
hydrazinolysis to 23 (97% yield).
The reaction of 23 with isophthalaldehyde was carried out
in dry ethanol in the presence of a catalytic amount of acetic
acid at 40 °C for 8 hours. As the mixture was heated, a solid was
already formed, changing from sticky to finely dispersed over
time. After the separation of this solid by using a centrifuge, the
pure product could be obtained by thoroughly washing with
ethanol. This procedure allowed the synthesis of 24 with
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starting materials have to be fully free of impurities or water,
that impede a clean precipitation of the imine derivative or
promoting the formation of open chained side products,
respectively. The subsequent reduction of 24 with sodium
borohydride in a mixture of dry methylene chloride and
methanol (1 : 1, v/v) gave 25 with 83% yield.
Conclusion
2,4,7-Tris(bromomethyl)-9,9-diethylfluorene (2) has been suc-
cessfully used for the syntheses of seventeen 9,9-diethylfluor-
enes consisting of three side-arms each bearing a heterocyclic,
bis(carboxymethyl)amino, bis(carbamoylmethyl)amino, bis(eth-
oxycarbonylmethyl)amino or an amino group (compounds 5–
Scheme 3. Syntheses of the imines 18 and 20 as well as the amines 19 and 21. Reagents and conditions: (a) dry MeOH, cat. AcOH, 24 h, room temperature
(74% of 18, 24% of 20); (b) dry MeOH, (EtO)3CH, 4 h, reflux; (c) dry MeOH, NaBH4, overnight, room temperature; (d) MeOH/H2O, 2 h, room temperature (44%
of 19); (e) dry CH2Cl2, molecular sieves (4 Å), 8 h, reflux; (f) dry CH2Cl2/MeOH, NaBH4, overnight, room temperature; (g) CH2Cl2/MeOH/H2O, 2 h, room
temperature (20% of 21).
Scheme 4. Syntheses of the 2,7-disubstituted derivatives 22 and 23 as well as of the fluorene-based macrocycles 24 and 25. Reagents and conditions: (a)
DMSO, 4 h, 80 °C (67% of 22); (b) EtOH/Toluene, N2H4 (64% aq. solution), 8 h, reflux (97% of 23); (c) dry EtOH, AcOH (cat. amount), 8 h, 40 °C (96% of 24); (d)
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21; see Figure 2). Imidazolyl, benzimidazolyl, pyrazolyl, pyrrolyl,
1,3-dioxoisoindolyl and pyridinium groups were taken into
account as heterocyclic units, attached to the aromatic skeleton
via   CH2  ,   CH2NHCH2  or   CH2N=CH  linkers. It is worth
noting that elegant methods have been developed to avoid the
problematic isolation of some target compounds. For example,
the ester-functionalized derivative 13 could be obtained in very
good yield by converting the bromomethyl substituted fluo-
renes, which are present in the crude mixture, into the
corresponding pyridinium derivatives. These could easily be
separated from the desired product.
Based on the knowledge gained from this study, the
syntheses of compounds displaying not identically substituted
side-arms are now in progress (for examples, see Figure 4). Both
the compounds 5–21 as well as the derivatives of the type
shown in Figure 4 are all potentially suitable to act as artificial
receptors. The design of the fluorene derivatives bearing
different functional groups is inspired by the results of binding
studies with benzene-based receptor molecules. These studies
revealed that compounds consisting of side-arms bearing
different types of functional groups (acting as recognition units)
are often more selective receptors than those that consist of
identical recognition units.
The fluorene-based macrocycles[24] 24 and 25 have been
successfully synthesized through the reaction of 2,7-bis
(aminomethyl)-9,9-diethylfluorene (23) with isophthalaldehyde.
The excellent yield of the macrocyclization reaction (96%) is
worth a special mention. The syntheses of further macrocycles
are now in progress and involve the preparation of compounds
with different substituents in the 9 position of the fluorene ring
(units X in the Figure 5a) as well as with different bridge units
(units Y). Such macrocycles are designed to recognize disac-
charides like β-maltoside, as shown in Figure 5b (in analogy to
the effective recognition of monosaccharides by benzene-based
macrocycles[14]).
Experimental Section
Melting points (uncorrected) were measured on a hot stage
microscope (Büchi 510). FT-IR spectra were obtained from a Perkin
Elmer FT-IR 1600 spectrometer as KBr pellet. 1H and 13C NMR
spectra were recorded on a Bruker Avance III-500 MHz spectrometer
using Me4Si as internal standard. Mass spectra were recorded on a
solariX 15T FT-ICR-MS (Bruker Daltonic). 1H-imidazole, 1H-benzimi-
dazole, 2-bromo-1H-benzimidazole 3,5-dimethyl-1H-pyrazole, 4-
bromo-1H-pyrazole, 4-bromo-3,5-dimethyl-1H-pyrazole, potassium
1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl, diethyl iminodiacetate, 1H-
imidazole-2-carbaldehyde, 1H-pyrrole-2-carbaldehyde and iso-
phthalaldehyde are commercially available. 2,4,7-Tris(bromometh-
yl)-9,9-diethylfluorene (2)[9] (for prior synthesis see ref [23]), 2,7-bis
(bromomethyl)-9,9-diethylfluorene (26)[23] and 4-iodo-3,5-dimethyl-
1H-pyrazole[25] were synthesized according to literature procedures.
General procedure for the synthesis of compounds 5–11
Route A: Compound 2, the corresponding heterocyclic compound
and N,N-diisopropylethylamine (DIPEA) were dissolved in THF and
the mixture was stirred at room temperature or refluxed. The
progress of the reaction was monitored by thin layer chromato-
graphy (TLC). The formed salts were filtered off and the solvent was
evaporated. The product was isolated by column chromatography,
using silica gel as stationary phase and CHCl3/MeOH (7n NH3) as
mobile phase.
Route B: The corresponding heterocyclic compound was dissolved
in dry THF under nitrogen atmosphere and NaH (60% dispersion in
mineral oil) was added in portions. The mixture was stirred for
30 min at room temperature. Compound 2 was dissolved in dry
THF and added dropwise to the reaction over a period of 15 min.
The reaction mixture was stirred at room temperature for 24 h or
refluxed for 8 h, cooled down and poured into water (20 ml). The
resulting slurry was extracted with CHCl3 (3×20 ml). The combined
organic layers were dried over Na2SO4. The solvent was evaporated
and the raw product purified by column chromatography, using
silica gel as stationary and CHCl3/EtOAc 5 :1 (v/v) as mobile phase.
2,4,7-Tris[(1H-imidazol-1-yl)methyl]-9,9-diethylfluorene (5). Route
A: Compound 2 (300 mg, 0.60 mmol), 1H-imidazol (163 mg,
2.39 mmol) and DIPEA (310 mg, 2.40 mmol) were dissolved in THF
(5 ml) and reacted at room temperature over 24 h. Purification by
column chromatography [CHCl3/MeOH (7n NH3) 25 :1 (v/v), Rf =
0.43] yielded 43% of 5 (118 mg, 0.255 mmol); Route B: Prepared
from 1H-imidazol (163 mg, 2.39 mmol), NaH (60% dispersion in
mineral oil; 96 mg, 2.40 mmol) in 5 ml dry THF and 2 (300 mg,
0.60 mmol; dissolved in 2 ml dry THF), stirred at room temperature.
Purification by column chromatography [CHCl3/MeOH (7n NH3)
25 :1 (v/v), Rf =0.43] yielded 80% of 5 (222 mg, 0.48 mmol); 1H NMR
(500 MHz, CDCl3): δ=0.22 (t, J=7.3 Hz, 6H), 1.97 (q, J=7.3 Hz, 4H),
5.13 (s, 2H), 5.20 (s, 2H), 5.55 (s, 2H), 6.62 (s, 1H), 6.85–6.88 (m, 1H),
Figure 4. Exemplary structures of 2,4,7-trisubstituted-9,9-diethylfluorenes with side-arms bearing different functional groups, which can be easily prepared
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6.90–6.93 (m, 1H), 6.94–6.97 (m, 1H), 7.05–7.08 (m, 1H), 7.09–7.12
(m, 3H), 7.13–7.15 (m, 2H), 7.49–7.50 (m, 1H), 7.50–7.54 (m, 2H),
7.56–7.58 (m, 1H). 13C-NMR (125 MHz, CDCl3): δ=8.4, 32.8, 49.0,
50.7, 50.8, 56.0, 119.1, 119.2, 119.4, 121.6, 122.0, 122.8, 125.9, 126.6,
130.0, 130.1, 131.0, 135.7, 136.0, 137.3, 137.5, 138.5, 140.2, 151.7,
152.5 ppm. IR (KBr): ῡ=3356, 3106, 2961, 2928, 2873, 2851, 1613,
1503, 1440, 1391, 1347, 1282, 1225, 1106, 1074, 1028, 1004, 906,




Route A: Compound 2 (300 mg, 0.60 mmol), 1H-benzimidazol
(280 mg, 2.37 mmol) and DIPEA (310 mg, 2.40 mmol) were dis-
solved in THF (5 ml) and reacted under reflux conditions over 8 h.
Purification by column chromatography [CHCl3/MeOH (7n NH3)
50 :1 (v/v), Rf =0.53] yielded 36% of 6 (132 mg, 0.215 mmol); Route
B: Prepared from 1H-benzimidazol (280 mg, 2.37 mmol), NaH (60%
dispersion in mineral oil; 95 mg, 2.38 mmol) in 5 ml dry THF and 2
(300 mg, 0.60 mmol; dissolved in 2 ml dry THF), under reflux
conditions. Purification by column chromatography [CHCl3/MeOH
(7n NH3) 50 :1 (v/v), Rf =0.53] yielded 87% of 6 (318 mg,
0.52 mmol); M.p. 160–162 °C. 1H NMR (500 MHz, CDCl3): δ=0.17 (t,
J=7.3 Hz, 6H), 1.85–1.92 (m, 4H), 5.28 (s, 2H), 5.42 (s, 2H), 5.70 (s,
2H), 6.69 (s, 1H), 7.05–7.09 (m, 3H), 7.15–7.19 (m, 2H), 7.22–7.24 (m,
2H), 7.25–7.30 (m, 4H), 7.32–7.37 (m, 1H), 7.46 (d, J=8.0 Hz, 1H),
7.75 (s, 1H), 7.79–7.81 (m, 1H), 7.82–7.84 (m, 1H), 7.85–7.88 (m, 2H),
7.95 (s, 1H) ppm. 13C NMR (125 MHz, CDCl3): δ=8.3, 32.8, 47.1, 48.9,
49.0, 56.0, 109.7, 109.9, 110.1, 120.5, 120.7, 121.7, 122.0, 122.4,
122.7, 123.0, 123.1, 123.4, 125.8, 126.6, 130.0, 133.7, 133.8, 133.9,
134.9, 135.2, 138.7, 140.2, 142.6, 142.9, 143.1, 143.9, 144.0, 151.8,
152.7 ppm. IR (KBr): ῡ=3083, 3053, 2960, 2925, 2872, 2852, 1613,
1585, 1492, 1456, 1361, 1330, 1284, 1261, 1200, 1177, 1005, 966,
929, 887, 862, 737, 621,582, 470, 424 cm  1. HRMS-ESI: C41H36N6
calcd. for [M+H]+ : 613.307422, found: 613.307435.
2,4,7-Tris[(2-bromo-1H-benzimidazol-1-yl)methyl]-9,9-diethyl-
fluorene (7). Route B: Prepared from 2-bromo-1H-benzimidazol
(1000 mg, 5.08 mmol), NaH (60% dispersion in mineral oil; 204 mg,
5.10 mmol) in 20 ml dry THF and 2 (770 mg, 1.54 mmol; dissolved
in 2 ml dry THF). Purification by column chromatography [chloro-
form/ethyl acetate 5 :1 (v/v), Rf =0.32] yielded 94% of 7 (1231 mg,
1.45 mmol); M.p. 222–224 °C. 1H NMR (500 MHz, CDCl3): δ=0.20 (t,
J=7.2 Hz, 6H), 1.83–1.95 (m, 4H), 5.17 (s, 2H), 5.51 (s, 2H), 5.77 (s,
2H), 6.26 (s, 1H), 6.91–6.94 (m, 1H), 6.99–7.01 (m, 1H), 7.03 (s, 1H),
7.06–7.10 (m, 1H), 7.12–7.16 (m, 1H), 7.17–7.21 (m, 2H), 7.22–7.27
(m, 3H), 7.28–7.31 (m, 1H), 7.63–7.65 (m, 1H), 7.71–7.76 (m, 2H),
7.78–7.80 (m, 1H) ppm. 13C NMR (125 MHz, CDCl3): δ=8.3, 32.7,
46.8, 48.9, 49.2, 55.9, 109.5, 109.7, 109.9, 119.5, 119.6, 119.7, 121.0,
122.0, 122.7, 122.9, 123.1, 123.3, 123.4, 123.6, 126.0, 129.8, 130.3,
130.4, 130.6, 134.5, 134.9, 135.3, 135.6, 137.5, 140.3, 143.1, 143.2,
143.4, 151.9, 152.4 ppm. IR (KBr): ῡ=3053, 2960, 2927, 2873, 2852,
1613, 1587, 1451, 1435, 1358, 1328, 1278, 1237, 1182, 1150, 1129,
1096, 1006, 984, 929, 862, 804, 736, 663, 569, 525, 474, 428 cm  1.
HRMS-ESI: C41H33Br3N6 calcd. for [M+H]
+ : 847.038959, found:
847.039265.
2,4,7-Tris[(3,5-dimethyl-1H-pyrazol-1-yl)methyl]-9,9-diethylfluor-
ene (8). Route A: Compound 2 (300 mg, 0.60 mmol), 3,5-dimethyl-
1H-pyrazol (230 mg, 2.39 mmol) and DIPEA (310 mg, 2.40 mmol)
were dissolved in THF (5 ml) and reacted under reflux conditions
over 16 h. Purification by column chromatography [CHCl3/MeOH
(7n NH3) 50 :1 (v/v), Rf =0.57] yielded 67% of 8 (220 mg,
0.40 mmol). Route B: Prepared from 3,5-dimethyl-1H-pyrazol
(230 mg, 2.39 mmol), NaH (60% dispersion in mineral oil; 96 mg,
2.40 mmol) in 5 ml dry THF and 2 (300 mg, 0.60 mmol; dissolved in
2 ml dry THF). Purification by column chromatography [chloroform/
ethyl acetate 5 :1 (v/v), Rf =0.32] yielded 82% of 8 (267 mg,
0.49 mmol); M.p. 159–161 °C. 1H NMR (500 MHz, CDCl3): δ=0.20 (t,
J=7.3 Hz, 6H), 1.86–1.97 (m, 4H), 2.01 (s, 3H), 2.05 (s, 3H), 2.14 (s,
3H), 2.22 (s, 3H), 2.27 (s, 6H), 5.14 (s, 2H), 5.30 (s, 2H), 5.59 (s, 2H),
5.71 (s, 1H), 5.78 (s, 1H), 5.87 (s, 1H), 5.89 (s, 1H), 6.89 (s, 1H), 6.99–
Figure 5. a) Schematic illustration of some planned fluorene-based macrocycles; b) Energy-minimized structure of a 1 :1 complex formed between methyl β-
maltoside and a fluorene-based macrocycle (Y=pyrrole-based bridge). MacroModel V.8.5, OPLS 2001 force field, MCMM, 50000 steps. Color code: receptor N,
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7.03 (m, 1H), 7.06–7.09 (m, 1H), 7.60 (d, J=8.0 Hz, 1H) ppm. 13C
NMR (125 MHz, CDCl3): δ=8.3, 10.9, 11.2, 13.5, 13.6, 32.8, 50.9, 52.8,
53.0, 55.6, 105.5, 105.6, 105.7, 119.6, 121.3, 121.8, 122.8, 125.4,
133.0, 136.1, 136.5, 136.9, 139.2, 139.9, 140.5, 147.4, 147.5, 147.9,
151.2, 151.3 ppm. IR (KBr): ῡ=2972, 2935, 2916, 2875, 2854, 1610,
1552, 1485, 1460, 1445, 1419, 1381, 1337, 1315, 1300, 1276, 1232,
1175, 1146, 1115, 1028, 1005, 974, 906, 880, 853, 836, 776, 742, 720,
701, 686, 665, 629, 594, 565, 484, 465 cm  1. HRMS-ESI: C35H42N6
calcd. for [M+H]+ : 547.354372, found: 547.354384.
2,4,7-Tris[(4-bromo-1H-pyrazol-1-yl)methyl]-9,9-diethylfluorene
(9). Route B: Prepared from 4-bromo-1H-pyrazol (968 mg,
6.59 mmol), NaH (60% dispersion in mineral oil; 264 mg,
6.60 mmol) in 20 ml dry THF and 2 (1000 mg, 2.00 mmol; dissolved
in 5 ml dry THF). Purification by column chromatography [chloro-
form/ethyl acetate 5 :1 (v/v), Rf =0.81] yielded 77% of 9 (1070 mg,
1.530 mmol); M.p. 127–128 °C. 1H NMR (500 MHz, CDCl3): δ=0.24 (t,
J=7.3 Hz, 6H), 1.98 (q, J=7.3 Hz, 4H), 5.32 (s, 2H), 5.33 (s, 2H), 5.66
(s, 2H), 6.62 (s, 1H), 7.13 (dd, J=8.0/1.5 Hz, 1H), 7.18 (d, J=1.5 Hz,
1H), 7.20–7.22 (m, 2H), 7.38–7.40 (m, 2H), 7.51–7.52 (m, 2H), 7.54 (d,
J=8.0 Hz, 1H), 7.56–7.57 (m, 1H) ppm. 13C NMR (125 MHz, CDCl3):
δ=8.5, 32.7, 54.9, 55.9, 56.4, 56.7, 93.5, 93.6, 122.2, 122.4, 123.0,
126.9, 127.1, 129.4, 129.5, 130.2, 135.1, 135.6, 139.0, 140.1, 140.2,
140.3, 140.4, 151.5, 152.5 ppm. IR (KBr): ῡ=3121, 2960, 2927, 2871,
2850, 1613, 1587, 1517, 1441, 1421, 1377, 1303, 1192, 1150, 1156,
1108, 1034, 989, 950, 883, 839, 794, 758, 727, 706, 677, 645, 603,




ethylfluorene (10). Route B: Prepared from 4-bromo-3,5-dimethyl-
1H-pyrazol (880 mg, 5.03 mmol), NaH (60% dispersion in mineral
oil; 203 mg, 5.08 mmol) in 20 ml dry THF and 2 (770 mg, 1.54 mmol;
dissolved in 2 ml dry THF). Purification by column chromatography
[chloroform/ethyl acetate 5 :1 (v/v), Rf =0.60] yielded 83% of 10
(996 mg, 1.271 mmol); M.p. 146–147 °C. 1H NMR (500 MHz, CDCl3):
δ=0.22 (t, J=7.3 Hz, 6H), 1.95 (q, J=7.3 Hz, 4H), 2.03 (s, 3H), 2.04
(s, 3H), 2.15 (s, 3H), 2.23 (s, 3H), 2.26 (s, 3H), 2.27 (s, 3H), 5.18 (s, 2H),
5.32 (s, 2H), 5.62 (s, 2H), 5.71 (s, 1H), 6.98 (s, 1H), 7.02–7.05 (m, 1H),
7.11–7.13 (m, 1H), 7.60 (d, J=7.9 Hz, 2H) ppm. 13C NMR (125 MHz,
CDCl3): δ=8.4, 10.1, 10.2, 10.5, 12.3, 12.4, 32.8, 52.0, 53.9, 54.3, 55.7,
94.5, 94.6, 94.7, 120.0, 121.6, 123.0, 125.7, 132.5, 135.5, 136.3, 136.8,
137.2, 137.3, 138.0, 140.4, 146.2, 146.7, 151.4, 151.6 ppm. IR (KBr):
ῡ=2961, 2918, 2874, 2852, 1613, 1548, 1473, 1421, 1378, 1310,
1212, 1122, 1067, 1037, 1003, 844, 818, 796, 744, 710, 694, 658, 590,




ylfluorene (11). Route B: Synthesis and purification were carried
out under the absence of light. Prepared from 4-iodo-3,5-dimethyl-
1H-pyrazole[24] (4240 mg, 19.1 mmol), NaH (60% dispersion in
mineral oil; 780 mg, 19.5 mmol) in 25 ml dry THF and 2 (2900 mg,
5.79 mmol; dissolved in 6 ml dry THF). Purification by column
chromatography [chloroform/ethyl acetate 5 :1 (v/v), Rf =0.60]
yielded 97% of 11 (5220 mg, 5.64 mmol); M.p. 174–176 °C. 1H NMR
(500 MHz, CDCl3): δ=0.22 (t, J=7.3 Hz, 6H), 1.95 (q, J=7.3 Hz, 4H),
2.06 (s, 3H), 2.09 (s, 3H), 2.19 (s, 3H), 2.25 (s, 3H), 2.27 (s, 3H), 2.29 (s,
3H), 5.22 (s, 2H), 5.36 (s, 2H), 5.66 (s, 2H), 5.78 (s, 1H), 6.98 (s, 1H),
7.03 (dd, J=7.9/1.5 Hz, 1H), 7.12 (d, J=1.5 Hz, 1H), 7.60 (d, J=
7.9 Hz, 1H) ppm. 13C NMR (125 MHz, CDCl3): δ=8.4, 11.8, 11.9, 12.1,
14.1, 14.2, 32.8, 52.1, 54.1, 54.3, 55.7, 63.1, 63.4, 120.0, 121.6, 121.7,
123.0, 125.7, 132.5, 135.6, 136.3, 136.7, 140.4, 140.6, 140.7, 141.4,
149.4, 149.5, 150.0, 151.3, 151.6 ppm. IR (KBr): ῡ=2958, 2920, 2872,
2851, 1614, 1537, 1456, 1417, 1377, 1359, 1310, 1242, 1209, 1172,
1121, 1055, 1003, 882, 839, 817, 796, 746, 710, 694, 658, 588, 508,
478 cm  1. HRMS-ESI: C35H39I3N6 calcd. for [M+H]
+ : 925.044312,
found: 925.044349.
Syntheses of compounds 12–17
2,4,7-Tris(pyridiniummethyl)-9,9-diethylfluorene tribromide (12).
Compound 2 (250 mg, 0.50 mmol) and pyridine (0.12 ml, 118 mg,
1.49 mmol) were refluxed in CHCl3 (30 ml) for 4 h. The formed oil
was separated and washed with CHCl3. The residue was transferred
into a crystalline solid by dissolving in MeOH and removing the
solvent again. Recrystallisation from acetone yielded 92% of 12
(338 mg, 0.46 mmol); M.p. 185–187 °C. 1H NMR (500 MHz, CD3OD):
δ=0.21 (t, J=7.4 Hz, 6H), 2.19 (q, J=7.4 Hz, 4H), 6.05 (s, 4H), 6.55
(s, 2H), 7.31 (s, 1H), 7.64 (dd, J=8.0/1.3 Hz, 1H), 7.85 (s, 1H), 7.91 (s,
1H), 7.94 (d, J=8.0 Hz, 1H), 8.17–8.22 (m, 4H), 8.22–8.25 (m, 2H),
8.64–8.70 (m, 2H), 8.70–8.74 (m, 1H), 9.12 (d, J=5.8 Hz, 2H), 9.25 (d,
J=6.3 Hz, 4H) ppm. 13C-NMR (125 MHz, CD3OD): δ=8.8, 33.5, 57.9,
63.2, 64.9, 65.5, 124.9, 125.5, 126.4, 129.6, 129.8, 129.9, 130.0, 130.1,
135.0, 135.2, 141.3, 141.8, 146.0, 146.1, 146.3, 147.5, 147.8, 153.9,
155.1 ppm. IR (KBr): ῡ=3434, 3409, 3376, 3344, 3261, 3048, 3022,
2958, 2931, 2870, 1645, 1626, 1577, 1487, 1474, 1461, 1445, 1422,
1378, 1361, 1344, 1318, 1253, 1213, 1200, 1190, 1164, 1147, 1101,
1047, 1025, 1003, 957, 889, 862, 834, 811, 793, 768, 747, 735, 708,
690, 663, 623, 573, 481, 472, 446 cm  1. HRMS-ESI: C35H36Br3N3 calcd.
for [M+Na]+ : 758.035157, found: 758.035536.
2,4,7-tris[N,N-bis(ethoxycarbonylmethyl)aminomethyl]-9,9-dieth-
ylfluorene (13). Compound 2 (2000 mg, 3.99 mmol) and diethyl
iminodiacetate were dissolved in a THF/MeCN (10 :15 ml) mixture
and K2CO3 (1840 mg, 13.3 mmol) was added. After refluxing for 8 h
and subsequent cooling to room temperature the solid was filtered
off and the solvent was removed under reduced pressure. The
residue was dissolved in 25 ml acetone and refluxed with pyridine
(1.0 ml, 980 mg, 12.4 mmol) for 4 h. The solvent was removed and
the residue dissolved in 25 ml CHCl3. The organic layer was washed
with water (3×15 ml), dried over Na2SO4 and concentrated in
vacuum. The raw product was eluted over a short column packed
with silica gel using CHCl3/EtOAc [5 :1 (v/v), Rf =0.69) as eluent
system. Yield 88% of 13 (2915 mg, 3.53 mmol) as a sticky oil; 1H
NMR (500 MHz, CDCl3): δ=0.22 (t, J=7.2 Hz, 6H), 1.23 (t, J=7.1 Hz,
6H), 1.27 (t, J=7.1 Hz, 6H), 1.28 (t, J=7.1 Hz, 6H), 2.00 (q, J=7.3 Hz,
4H), 3.55 (s, 4H), 3.57 (s, 4H), 3.60 (s, 4H), 3.98 (s, 2H), 4.00 (s, 2H),
4.14 (q, J=7.2 Hz, 4H), 4.17 (q, J=7.2 Hz, 4H), 4.18 (q, J=7.2 Hz,
4H), 4.37 (s, 2H), 7.29–7.32 (m, 3H), 7.34 (s, 1H), 7.95 (d, J=7.9 Hz, 1
H) ppm. 13C NMR (125 MHz, CDCl3): δ=8.4, 14.3, 33.0, 54.1, 54.2,
55.3, 56.1, 58.0, 60.4, 122.5, 123.0, 123.9, 127.9, 130.0, 132.2, 136.5,
136.6, 139.6, 140.8, 150.7, 151.4, 171.2, 171.3 ppm. IR (KBr): ῡ=2979,
2962, 2931, 2916, 2908, 2874, 2851, 1729, 1446, 1413, 1394, 1369,
1346, 1297, 1261, 1184, 1149, 1095, 1027, 987, 918, 873, 844, 825,
800, 750, 665, 588, 490 cm  1. HRMS-ESI: C44H63N3O12 calcd. for [M+
H]+ : 826.448451, found: 826.448502.
2,4,7-tris[N,N-bis(carbamoylmethyl)aminomethyl]-9,9-diethyl-
fluorene (14). Compound 13 (900 mg, 1.09 mmol) was stirred in a
7n methanolic ammonia solution (15 ml) for 7 d. The mixture was
poured into ether (30 ml), the precipitate was filtered off and
repeatedly washed with ether. Yield 71% of 14 (505 mg,
0.78 mmol); M.p. 124–126 °C. 1H NMR (500 MHz, CD3OD): δ=0.18 (t,
J=7.3 Hz, 6H), 2.04–2.12 (m, 4H), 3.23 (s+ s, 8H), 3.39 (s, 4H), 3.82 (s,
4H), 4.26 (s, 2H), 7.35 (d, J=1.5 Hz, 1H), 7.38 (dd, J=8.0/1.7 Hz, 1H),
7.40 (d, J=1.5 Hz, 1H), 7.45 (d, J=1.7 Hz, 1H), 7.94 (d, J=8.0 Hz, 1H)
ppm. 13C-NMR (125 MHz, CD3OD): δ=8.8, 34.0, 56.7, 58.4, 58.6, 58.7,
60.2, 60.4, 124.5, 125.1, 129.6, 131.7, 133.5, 137.4, 141.1, 142.3,
152.3, 152.9, 176.3, 176.4 ppm. IR (KBr): ῡ=3550-3000, 2961, 2916,
2871, 2847, 1651, 1444, 1394, 1373, 1335, 1298, 1119, 1097, 978,




ene hexasodium salt (15a). Compound 13 (900 mg, 1.09 mmol)
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NaOH solution (10 ml) was added. The reaction was stirred at room
temperature for 24 h. After removing the solvent under reduced
pressure, the residue was extracted with cold ethanol. The solvent
was removed and the obtained solid dried in vacuum. Yield 51% of
15a (441 mg, 0.56 mmol); M.p. 150–152 °C. 1H NMR (500 MHz,
CD3OD): δ=0.18 (t, J=7.3 Hz, 6H), 2.00–2.13 (m, 4H), 3.06 (s, 4H),
3.18 (s, 8H), 3.57 (s, 2H), 3.87 (s, 2H), 4.03 (s, 2H), 7.13 (s, 1H), 7.34 (s,
1H), 7.40 (d, J=7.9 Hz, 1H), 7.88 (s, 1H), 8.01 (d, J=7.9 Hz, 1H) ppm.
13C-NMR (125 MHz, CD3OD): δ=8.8, 34.1, 56.5, 56.6, 59.4, 59.8, 60.2,
60.7, 123.8, 124.3, 125.9, 130.1, 132.2, 135.6, 136.3, 139.4, 139.9,
142.7, 151.8, 152.1, 177.5, 178.7, 179.1 ppm. IR (KBr): ῡ=3550-3000
(H2O), 2965, 2923, 2876, 1557, 1397, 1331, 1249, 1116, 1047, 1013,
995, 830, 701, 645, 619, 464 cm  1. HRMS-ESI: C32H33N3Na6O12 calcd.
for [M  Na]  : 766.155820, found: 766.160412.
2,4,7-Tris[N,N-bis(carboxylmethyl)aminomethyl]-9,9-diethylfluor-
ene (15b). Compound 13 (250 mg, 0.30 mmol) was dissolved in dry
MeOH (5 ml) and a solution of KOH (200 mg, 3.56 mmol) in dry
MeOH (5 ml) was added dropwise to the reaction over the course
of 15 minutes. The mixture was stirred at 40 °C for 8 h and then the
solvent was removed under reduced pressure. The residue was
treated with 2n HCl (10 ml) at room temperature for 60 min. The
aqueous phase was concentrated to about a third of the volume
and then poured into acetone. The precipitate was filtered off and
dried under vacuum. The solid was then extracted with dry DMSO.
After removal of the solvent and long drying under high vacuum,
the product was obtained from the organic phase as a white solid.
Yield 72% of 15b (143 mg, 0.22 mmol); M.p. 165–167 °C. 1H NMR
(500 MHz, DMSO-d6): δ=0.18 (t, J=7.3 Hz, 6H), 1.98–2.05 (m, 4H),
3.84 (s, 4H), 4.13 (s, 4H), 4.14 (s, 2H), 4.52 (s, 2H), 4.60 (s,2H), 7.57 (d,
J=8.1 Hz, 1H), 7.64 (s, 1H), 7.66 (s, 2H), 8.19 (d, J=8.1 Hz, 1H). 13C
NMR (125 MHz, DMSO-d6): δ=8.3, 32.2, 53.5, 53.6, 53.7, 55.2, 58.7,
124.2, 124.3, 126.0, 126.1, 129.0, 130.7, 133.8, 140.8, 141.0, 150.9,
151.7, 167.5, 170.3 ppm. IR (KBr): ῡ=3550–3000 (H2O), 3000–2300,
2962, 2931, 2874, 2856, 1732, 1622, 1398, 1360, 1193, 1080, 1047,
1023, 941, 872, 822, 802, 752, 710, 652, 625, 530, 490, 465 cm  1.
HRMS-ESI: C32H39N3O12 calcd. for [M  H]
  : 656.245000, found:
656.247831.
2,4,7-Tris[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-9,9-di-
ethylfluorene (16). Potassium phthalimide (4000 mg, 21.6 mmol)
was suspended in DMSO (15 ml) and heated to 80 °C. Compound 2
(3000 mg, 5.99 mmol) was added in portions over a period of
15 min. After stirring for 4 h at 80 °C the mixture was poured into
water (50 ml). The precipitate was filtered off, washed with water
and dissolved in chloroform. Again the organic phase was washed
with water and dried over Na2SO4. The solvent was removed under
reduced pressure and the raw product was recrystallized from THF/
CHCl3. Yield 91% of 16 (3810 mg, 5.45 mmol); M.p. 240 °C. 1H NMR
(500 MHz, CDCl3): δ=0.27 (t, J=7.3 Hz, 6H), 1.94–2.02 (m, 4H), 4.77
(s, 2H), 4.92 (s, 2H), 5.29 (s, 2H), 7.03 (s, 1H), 7.27 (s, 1H), 7.42–7.46
(m, 2H), 7.64–7.68 (m, 2 H), 7.69–7.73 (m, 2H), 7.73–7.77 (m, 2H),
7.77–7.80 (m, 2H), 7.80–7.82 (m, 1H), 7.84–7.88 (m, 2H), 7.89–7.93
(m, 2H) ppm. 13C-NMR (125 MHz, CDCl3): δ=8.6, 32.7, 39.7, 41.7,
41.8, 55.6, 122.1, 123.3, 123.4, 123.6, 124.6, 127.5, 130.8, 132.1,
132.2, 133.8, 134.0, 134.1, 135.0, 135.3, 137.5, 140.6, 151.4, 152.0,
167.9, 168.1, 168.2 ppm. IR (KBr): ῡ=3460, 3063, 2960, 2932, 2871,
2858, 1765, 1709, 1613, 1465, 1426, 1389, 1332, 1238, 1212, 1186,
1170, 1108, 1097, 1084, 1072, 1047, 1038, 1004, 991, 958, 952, 935,
929, 898, 889, 874, 846, 823, 794, 767, 744, 721, 707, 680, 659, 640,
622, 605, 563, 529, 513, 464, 422, 409 cm  1. HRMS-ESI: calcd. for
C44H33N3O6 [M+H]
+ : 700.244212, found: 700.244210.
2,4,7-Tris(aminomethyl)-9,9-diethylfluorene (17). Compound 16
(1000 mg, 1.43 mmol) was suspended in a 2 :1 (v/v) mixture of
ethanol/toluene (2 :1 v/v, 60 ml) and hydrazine (64% solution in
water, 1 ml, 640 mg, 20.0 mmol) was added. After refluxing for 8 h
the solvent was removed under reduced pressure and the
remaining solid dissolved in 2 n KOH solution. The aqueous phase
was extracted with CH2Cl2 (20 ml). The combined organic layers
were dried over Na2SO4 and the solvent was removed in vacuum,
yielding the product in pure form. Yield 84% of 17 (370 mg,
1.20 mmol); M.p. 93–94 °C. 1H NMR (500 MHz, CDCl3): δ=0.27 (t, J=
7.3 Hz, 6H), 2.02 (q, J=7.3 Hz, 4H), 3.95 (s, 4H), 4.28 (s, 2H), 7.18 (s,
1H), 7.24 (s, 1H), 7.27–7.30 (m, 2H), 7.72–7.76 (m, 1H) ppm. 13C-NMR
(125 MHz, CDCl3): δ=8.5, 33.0, 44.9, 46.7, 55.5, 119.9, 121.5, 122.4,
125.1, 126.0, 137.2, 137.7, 140.1, 141.8, 142.2, 151.0, 151.4 ppm. IR
(KBr): ῡ=3356, 3279, 3181, 2960, 2914, 2872, 2850, 1591, 1452,
1417, 1375, 1340, 1169, 1051, 1003, 989, 955, 866, 822, 744, 690,
558, 486 cm  1. HRMS-LDI: C20H27N3 calcd. for [M · ]
+ : 309.219949,
found: 309.219950.
Synthesis of compounds 18–21
2,4,7-Tris[N-(1H-imidazol-2-yl-methylidene)aminomethyl]-9,9-di-
ethylfluorene (18). Under N2-atmosphere compound 17 (200 mg,
0.65 mmol) and imidazole-2-carbaldehyde (205 mg, 2.13 mmol)
were dissolved in dry methanol (1 ml). A catalytic amount of acetic
acid was added and the mixture stirred for 24 h at room temper-
ature. The solution was filtered, the solvent removed and the
residue dissolved in dry CHCl3. The solution was poured into
diethylether and the precipitate was filtered off. Dissolving in CHCl3
and repeated precipitation yielded 74% of 18 (260 mg, 0.48 mmol)
as a white solid. M.p. 146–147 °C. 1H NMR (500 MHz, CDCl3): δ=0.16
(t, J=7.3 Hz, 6H), 1.88 (q, J=7.3 Hz, 4H), 4.71 (s, 2H), 4.80 (s, 2H),
5.02 (s, 2H), 6.93–7.18 (br s, 6H), 7.04–7.08 (m, 2H), 7.10 (s, 1H), 7.16
(s, 1H), 7.58 (d, J=8.0 Hz, 1H), 8.33 (s, 1H), 8.35 (s, 1H), 8.39 (s, 1H)
ppm. 13C-NMR (125 MHz, CDCl3): δ=8.6, 32.8, 55.6, 61.8, 64.5, 64.7,
118.9, 121.7, 122.5, 123.0, 126.9, 127.6, 130.5, 132.8, 136.9, 137.2,
138.0, 140.2, 144.7, 151.1, 151.6, 153.2, 153.8 ppm. IR (KBr): ῡ=
3500–2500, 3110, 3030, 2963, 2914, 2875, 2850, 2821, 1645, 1543,
1442, 1394, 1344, 1301, 1155, 1106, 1034, 998, 922, 873, 823, 759,




fluorene (19). Under N2-atmosphere compound 17 (200 mg,
0.65 mmol) and imidazole-2-carbaldehyde (248 mg, 2.59 mmol)
were dissolved in dry methanol (5 ml). Triethyl orthoformate (5 ml,
4455 mg, 30.1 mmol) was added and the reaction refluxed for 4 h.
After cooling down to room temperature, NaBH4 (130 mg,
3.45 mmol) was added in portions. The mixture was stirred over-
night at room temperature. Water (20 ml) was added afterwards
and stirring continued for another 2 h. The precipitated organic
phase was separated and dried in vacuo. The product was isolated
by column chromatography [chloroform/methanol 2 : 1 (v/v)+2.0%
NH3, Rf =0.35]. Yield 44% of 19 (158 mg, 0.29 mmol); M.p. 100–
102 °C. 1H NMR (500 MHz, CD3OD): δ=0.19 (t, J=7.3 Hz, 6H), 2.05
(q, J=7.3 Hz, 4H), 3.81 (s, 2H), 3.82 (s, 2H), 3.87 (s, 4H), 4.00 (s, 2H),
4.13 (s, 2H), 7.00 (s+ s, 4H), 7.05 (s, 2H), 7.24–7.27 (m, 1H), 7.28 (s,
1H), 7.29 (s, 1H), 7.37 (s, 1H), 7.48 (d, J=7.9 Hz, 1H) ppm. 13C NMR
(125 MHz, CD3OD): δ=8.8, 34.0, 46.3, 46.4, 46.7, 51.8, 54.0, 56.8,
122.7, 122.9, 123.9, 128.6, 129.4, 135.0, 139.1, 139.3, 139.7, 141.8,
147.9, 148.0, 152.1, 152.5 ppm. IR (KBr): ῡ=3144, 3043, 2961, 2912,
2873, 2844, 2821, 2663, 1666, 1556, 1448, 1375, 1338, 1213, 1155,
1097, 986, 858, 822, 797, 739, 663, 481 cm  1. HRMS-ESI: C32H39N9
calcd. for [M+H]+ : 550.340119, found: 550.340119.
2,4,7-Tris[N-(1H-pyrrol-2-yl-methylidene)aminomethyl]-9,9-dieth-
ylfluorene (20). Under N2-atmosphere compound 17 (200 mg,
0.65 mmol) and pyrrole-2-carbaldehyde (200 mg, 2.10 mmol) were
dissolved in dry degassed methanol (1 ml). A catalytic amount of
acetic acid was added and the mixture stirred for 24 h at room
temperature. The precipitate was filtered off. Dissolving in CHCl3
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as a white solid. M.p. >202 °C decomposition. 1H NMR (500 MHz,
CDCl3): δ=0.27 (t, J=7.3 Hz, 6H), 1.98 (q, J=7.3 Hz, 4H), 4.76 (s,
2H), 4.79 (s, 2H), 5.09 (s, 2H), 6.10–6.12 (m, 1H), 6.17–6.19 (m, 1H),
6.20–6.23 (m, 1H), 6.39–6.42 (m, 1H), 6.48–6.50 (m, 1 H), 6.52–6.54
(m, 1 H), 6.58–6.60 (m, 1 H), 6.76–6.78 (m, 1 H), 6.81–6.83 (m, 1 H),
7.13 (s, 1H), 7.21–7.25 (m, 2 H), 7.27 (s, 1H), 7.71 (d, J=7.8 Hz, 1H),
8.02 (s, 1H), 8.15 (s, 1H), 8.18 (s, 1H) ppm. 13C NMR (125 MHz, CDCl3):
δ=8.6, 33.0, 55.6, 61.5, 64.5, 64.8, 109.4, 109.6, 109.7, 114.8, 114.9,
115.0, 121.0, 122.2, 122.3, 122.4, 123.0, 126.7, 127.1, 130.0, 130.1,
134.1, 137.8, 138.1, 140.5, 151.0, 151.1, 152.7, 153.0 ppm. IR (KBr):
ῡ=3500–2500, 3110, 3030, 2963, 2914, 2875, 2850, 2821, 1645,
1543, 1442, 1394, 1344, 1301, 1155, 1106, 1034, 998, 922, 873, 823,
759, 709, 659, 613, 505, 470 cm  1. HRMS-ESI: C35H36N6 calcd. for [M
+H]+ : 541.307422, found: 541.307426.
2,4,7-Tris[N-(1H-pyrrol-2-yl-methyl)aminomethyl]-9,9-diethylfluor-
ene (21). Under N2-atmosphere compound 17 (200 mg, 0.65 mmol)
and pyrrole-2-carbaldehyde (203 mg, 2.15 mmol) were dissolved in
dry CH2Cl2 (5 ml). Molecular sieves (4 Å) were added and the
reaction refluxed for 8 h. After cooling down to room temperature
the drying agent was filtered off and dry methanol (2 ml) added.
NaBH4 (410 mg, 10.84 mmol) was added in portions and the
mixture stirred overnight at room temperature. Water (20 ml) was
added afterwards and stirring continued for another 2 h. The
precipitated organic phase was separated and dried in vacuo. The
product was isolated by column chromatography [CHCl3/MeOH (7n
NH3) 25 :1 (v/v), Rf =0.18]. Yield 20% of 21 (72 mg, 0.13 mmol);
M.p. 110–112 °C. 1H NMR (500 MHz, CDCl3): δ=0.24 (t, J=7.3 Hz,
6H), 1.98 (q, J=7.3 Hz, 4H), 3.80 (s, 2H), 3.81 (s, 2H), 3.82 (s, 2H), 3.84
(s, 2H), 3.90 (s, 2H), 4.13 (s, 2H), 6.02–6.05 (m, 2H), 6.07–6.10 (m, 1H),
6.11–6.15 (m, 3H), 6.67–6.69 (m, 2H), 6.69–6.71 (m, 1 H), 7.14 (s, 1H),
7.18 (s, 1H), 7.19–7.23 (m, 1 H), 7.24 (s, 1H), 7.52 (d, J=7.9 Hz, 1H),
8.94 (br s, 2H), 8.98 (br s, 1H) ppm. 13C-NMR (125 MHz, CDCl3): δ=
8.6, 33.0, 45.8, 45.9, 46.4, 51.5, 53.3, 55.5, 106.5, 106.6, 106.8, 108.0,
117.5, 121.5, 122.5, 122.6, 127.2, 128.0, 130.2, 130.3, 134.2, 138.1,
138.4, 138.5, 140.3, 150.9, 151.4 ppm. IR (KBr): ῡ=3361, 3196, 3097,
2962, 2922, 2872, 2850, 1568, 1446, 1344, 1293, 1238, 1165, 1095,
1024, 957, 883, 797, 716, 560 cm  1. HRMS-ESI: C35H42N6 calcd. for [M
+H]+ : 547.354372, found: 547.354367.
Synthesis of compounds 22–25
2,7-Bis[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-9,9-dieth-
ylfluorene (22). Potassium phthalimide (1700 mg, 9.18 mmol) was
suspended in DMSO (15 ml) and heated to 80 °C. Compound 26
(1500 mg, 3.67 mmol) was added in portions over a period of
15 min. After stirring for 4 h at 80 °C the mixture was poured into
water (50 ml). The precipitate was filtered off, washed with water
and dissolved in chloroform. Again the organic phase was washed
with water and dried over Na2SO4. The solvent was removed under
reduced pressure and the raw product was recrystallized from THF/
CHCl3. Yield 67% of 22 (1331 mg, 2.46 mmol); M.p. 280–281 °C.
1H
NMR (500 MHz, CDCl3): 0.29 (t, J=7.3 Hz, 6H), 1.98 (q, J=7.3 Hz,
4H), 4.89 (s, 4H), 7.36–7.40 (m, 4H), 7.59 (d, J=7.7 Hz, 2H), 7.68–7.72
(m, 4H), 7.83–7.87 (m, 4H) ppm. 13C-NMR (125 MHz, CDCl3): δ=8.6,
32.4, 42.0, 56.0, 119.8, 123.4, 123.6, 127.5, 132.2, 134.0, 135.2, 140.7,
150.8, 168.1 ppm. IR (KBr): ῡ=3460, 3063, 2960, 2932, 2871, 2858,
1765, 1709, 1613, 1465, 1426, 1389, 1332, 1316, 1276, 1263, 1212,
1186, 1162, 1084, 1008, 943, 929, 896, 842, 812, 798, 750, 733, 719,
709, 690, 661, 600, 566, 529, 521, 464, 434, 404 cm  1. HRMS-ESI:
C35H28N2O4 calcd. for [M+H]
+ : 541.212184, found: 541.212185.
2,7-Bis(aminomethyl)-9,9-diethylfluorene (23). Compound 22
(2000 mg, 3.70 mmol) was suspended in a 2 :1 (v/v) mixture of
ethanol/toluene (2 :1 v/v, 150 ml) and hydrazine (64% solution in
water, 1 ml, 640 mg, 20.0 mmol) was added. After refluxing for 8 h
the solvent was removed under reduced pressure and the
remaining solid dissolved in 2 n KOH solution. The aqueuos phase
was extracted with toluene (3×20 ml). The combined organic layers
were dried over Na2SO4 and the solvent was removed in vacuum.
The product was obtained as a pale yellow solid. Yield 97% of 23
(1.01 g, 3.60 mmol); M.p. 34–35 °C.1H NMR (500 MHz, CDCl3): δ=
0.31 (t, J=7.4 Hz, 6H), 2.02 (q, J=7.4 Hz, 4H), 3.93 (s, 4H), 7.23–7.27
(m, 4H), 7.63 (d, J=7.6 Hz, 2H) ppm. 13C NMR (125 MHz, CDCl3): δ=
8.6, 32.7, 46.8, 56.0, 119.4, 121.5, 125.8, 140.2, 142.2, 150.4 ppm. IR
(KBr): ῡ=3342, 3267, 3183, 3061, 3042, 2995, 2963, 2913, 2873,
2850, 1606, 1458, 1417, 1375, 1328, 1317, 1299, 1214, 1159, 1129,
1091, 1045, 1005, 967, 942, 885, 862, 839, 806, 744, 723, 688, 553,
541, 509, 468, 420 cm  1. HRMS-LDI: C19H24N2 calcd. for [M · ]
+ :
280.193400, found: 280.193398.
Macrocycle 24. Amine 23 (100 mg, 0.36 mmol) was dissolved in dry
ethanol (4 ml) and isophthalic aldehyde (48 mg, 0.36 mmol) added.
A catalytic amount of acetic acid was added and the reaction
mixture stirred for 8 h at 40 °C. The precipitated solid was filtered
off, washed with dry ethanol and dried under vacuum. Yield 96% of
24 (129 mg, 0.17 mmol); M.p. 162–164 °C. 1H NMR (500 MHz, CDCl3):
δ=0.33 (t, J=7.1 Hz, 12H), 2.01 (q, J=7.1 Hz, 8H), 4.90 (s, 8H), 7.26–
7.28 (m, 8H), 7.48 (t, J=7.6 Hz, 2H), 7.65 (d, J=7.8 Hz, 4H), 7.90 (d,
J=7.6 Hz, 4H), 8.16 (s, 2H), 8.45 (s, 4H) ppm. 13C NMR (125 MHz,
CDCl3): δ=8.8, 32.8, 56.2, 65.5, 119.7, 122.7, 126.9, 128.7, 129.1,
130.3, 136.8, 137.8, 140.5, 150.6, 161.4 ppm. IR (KBr): ῡ=3055, 3034,
3007, 2961, 2928, 2915, 2871, 2847, 1641, 1604, 1583, 1463, 1448,
1417, 1373, 1317, 1290, 1265, 1205, 1154, 1084, 1033, 997, 939, 885,
812, 744, 688, 648, 546, 511, 474, 447, 422 cm  1. HRMS-ESI: C54H52N4
calcd. for [M+H]+ : 757.426474, found: 757.426477.
Macrocycle 25. Imine 24 (100 mg, 0.13 mmol) was dissolved in dry
CH2Cl2 (2 ml) and dry methanol (2 ml) was added. NaBH4 (100 mg,
2.64 mmol) was added in portions and the mixture stirred overnight
at room temperature. Water (10 ml) was added afterwards and
stirring continued for another 2 h. The organic layer was separated,
washed with water (3×10 ml) and dried over Na2SO4. Removing the
solvent under vacuum yielded 83% of 25 (84 mg, 0.11 mmol).
M.p. 70–72 °C. 1H NMR (500 MHz, CDCl3): δ=0.30 (t, J=7.3 Hz, 12H),
2.01 (q, J=7.3 Hz, 8H), 3.83 (s, 8H), 3.88 (s, 8H), 7.21–7.36 (m, 16H),
7.60–7.64 (m, 4H) ppm. 13C NMR (125 MHz, CDCl3): δ=8.6, 32.8,
53.1, 53.6, 55.9, 119.4, 122.6, 126.9, 128.2, 128.5, 138.9, 140.4, 140.5,
150.2 ppm. IR (KBr): ῡ=3306, 3184, 3053, 3026, 3003, 2960, 2915,
2871, 2848, 1606, 1449, 1417, 1373, 1311, 1210, 1160, 1105, 1086,
1034, 1006, 938, 887, 812, 786, 744, 696, 590, 494, 464, 424 cm  1.
HRMS-ESI: C54H60N4 calcd. for [M+H]
+ : 765.489074, found:
765.489081.
Supporting Information
Supporting Information available. 1H und 13C NMR spectra of
compounds 5–25 (Figures S1–S54).
Acknowledgment
Financial support from the Federal German Ministry of Education
and Research (BMBF, Bundesministerium für Bildung und For-
schung) is gratefully acknowledged. Open access funding by the
Publication Fund of the TU Bergakademie Freiberg. Open access




1212ChemistryOpen 2020, 9, 1202–1213 www.chemistryopen.org © 2020 The Authors. Published by Wiley-VCH GmbH
Wiley VCH Mittwoch, 25.11.2020



























































The authors declare no conflict of interest.
Keywords: artificial receptors · fluorenophane · heterocycles ·
imines · macrocyclization
[1] a) T. P. I. Saragi, T. Spehr, A. Siebert, T. Fuhrmann-Lieker, J. Salbeck,
Chem. Rev. 2007, 107, 1011–1065; b) M. Irfan, K. D. Belfield, A. Saeed,
RSC Adv. 2015, 5, 48760–48768; c) Y. Ie, A. Uchida, N. Kawaguchi, M.
Nitani, H. Tada, F. Kakiuchi, Y. Aso, Org. Lett. 2016, 18, 4320–4323; d) Y.-
Y. Liu, J.-Y. Lin, Y.-F. Bo, L.-H. Xie, M.-D. Yi, X.-W. Zhang, H.-M. Zhang, T.-
P. Loh, W. Huang, Org. Lett. 2016, 18, 172–175; e) C. Poriel, J. Rault-
Berthelot, J. Mater. Chem. C 2017, 5, 3869–3897; f) L. Sicard, O. Jeannin,
J. Rault-Berthelot, C. Quinton, C. Poriel, ChemPlusChem 2018, 83, 874–
880; g) K. R. J. Thomas, A. Baheti, Mater. Technol. 2013, 28, 71–87; h) J.
Shaya, F. Fontaine-Vive, B. Y. Michel, A. Burger, Chem. Eur. J. 2016, 22,
10627–10637; i) I. V. Kurdyukova, A. A. Ishechenko, Russ. Chem. Rev.
2012, 81, 258–290.
[2] a) X. Guo, M. Baumgarten, K. Müllen, Prog. Polym. Sci. 2013, 38, 1832–
1908; b) R. Abbel, A. P. H. J. Schenning, E. W. Meier, J. Polym. Sci. Part A
2009, 47, 4215–4233; c) S.-A. Chen, H.-H. Lu, C. W. Huang, Adv. Polym.
Sci. 2008, 212, 49–84; d) U. Scherf, E. J. W. List, Adv. Mater. 2002, 14,
477–487; e) Y. Wu, D. Wu, H. Zhao, J. Li, X. Li, Z. Wang, H. Wang, F. Zhu,
B. Xu, RSC Adv. 2019, 9, 22176–22184; f) N. Giuseppone, G. Fuks, J.-M.
Lehn, Chem. Eur. J. 2006, 12, 1723–1735.
[3] a) L. Zhu, J. Qin, C. Yang, Chem. Commun. 2010, 46, 8755–8757; b) C.-S.
Wu, Y.-J. Lin, Y. Chen, Org. Biomol. Chem. 2014, 12, 1419–1429; c) S. W.
Thomas, G. D. Joly, T. M. Swager, Chem. Rev. 2007, 107, 1339–1386; d) T.
Yang, Y. Zuo, Y. Zhang, Z. Gou, X. Wang, W. Lin, J. Mater. Chem. B 2019,
7, 4649–4654.
[4] a) R. Hosseinzadeh, M. Mohadjerani, M. Pooryousef, Anal. Bioanal. Chem.
2016, 408, 1901–1908; b) A. S. Tanwar, S. Hussain, A. H. Malik, M. A.
Afroz, P. K. Iyer, ACS Sens. 2016, 1, 1070–1077.
[5] S. Oger, D. Schapman, R. Mougeot, S. Leleu, N. Lascoux, P. Baldeck, M.
Bénard, T. Gallavardin, L. Galas, X. Franck, Chemistry 2019, 25, 10954–
10964.
[6] a) N. Zehra, D. Dutta, A. H. Malik, S. S. Ghosh, P. K. Iyer, ACS Appl. Mater.
Interfaces 2018, 10, 27603–27611; b) I. H. Bae, H. S. Kim, Y. You, C.
Chough, W. Choe, M. K. Seon, S. G. Lee, G. Keum, S. K. Jang, B.
Moon Kim, Eur. J. Med. Chem. 2015, 101, 163–178.
[7] a) L. Wang, T. Zhuang, F. Li, W. Wei, Environ. Sci. Pollut. Res. Int. 2019, 26,
27407–27413; b) E. M. Hussein, R. I. Alsantali, S. M. Abd El-Galil, R. J.
Obaid, A. Alharbi, M. A. S. Abourehab, S. A. Ahmed, Heliyon 2019, 5,
e01982.
[8] a) S. R. Chowdhury, S. Mondal, B. Muthuraj, S. N. Balaji, V. Trivedi, P. K.
Iyer, ACS Omega 2018, 3, 8059–8066; b) M. T. Gabr, M. S. Abdel-Raziq,
Chem. Biodiversity 2018, 15, e1800244.
[9] P. Seidel, A. Schwarzer, M. Mazik, Eur. J. Org. Chem. 2019, 1493–1502.
[10] For examples of acyclic benzene-based carbohydrate receptors re-
ported by our group, see: a) M. Stapf, W. Seichter, M. Mazik, Eur. J. Org.
Chem. 2020, 4900–4915; b) S. Kaiser, C. Geffert, M. Mazik, Eur. J. Org.
Chem. 2019, 7555–7562; c) N. Koch, W. Seichter, M. Mazik, Synthesis
2016, 48, 2757–2767; d) J. Lippe, W. Seichter, M. Mazik, Org. Biomol.
Chem. 2015, 13, 11622–11632; e) C. Geffert, M. Mazik, J. Org. Chem.
2013, 78, 292–300; f) J.-R. Rosien, W. Seichter, M. Mazik, Org. Biomol.
Chem. 2013, 11, 6569–6579; g) C. Sonnenberg, A. Hartmann, M. Mazik,
Nat. Prod. Commun. 2012, 7, 321–326; h) M. Mazik, A. Hartmann,
Beilstein J. Org. Chem. 2010, 6, No. 9; i) M. Mazik, M. Kuschel, Chem. Eur.
J. 2008, 14, 2405–2419; j) M. Mazik, H. Cavga, J. Org. Chem. 2007, 72,
831–838; k) M. Mazik, C. Geffert, Org. Biomol. Chem. 2011, 9, 2319–2326;
l) M. Mazik, W. Radunz, R. Boese, J. Org. Chem. 2004, 69, 7448–7462;
m) M. Mazik, W. Sicking, Chem. Eur. J. 2001, 7, 664–670; n) M. Mazik, H.
Bandmann, W. Sicking, Angew. Chem. Int. Ed. 2000, 39, 551–554; Angew.
Chem. 2000, 112, 562–565; o) M. Mazik, W. Radunz, W. Sicking, Org. Lett.
2002, 4, 4579–4582; For reviews, see:; p) M. Mazik, Chem. Soc. Rev. 2009,
38, 935–956; q) M. Mazik, RSC Adv. 2012, 2, 2630–2642; r) L. Köhler, W.
Seichter, M. Mazik, Eur. J. Org. Chem. 2020, DOI: 10.1002/
ejoc.202001101.
[11] For examples of tripodal and hexapodal benzene derivatives with the
ability to complex ammonium ions, see: a) J. Chin, J. Oh, S. Y. Jon, S. H.
Park, C. Walsdorff, B. Stranix, A. Ghoussoub, S. J. Lee, H. J. Chung, S.-M.
Park, K. Kim, J. Am. Chem. Soc. 2002, 124, 5374–5379; b) M.
Arunachalam, B. N. Ahamed, P. Ghosh, Org. Lett. 2010, 12, 2742–2745;
c) N. Koch, W. Seichter, M. Mazik, Tetrahedron 2015, 71, 8965–8974;
d) M. Schulze, N. Koch, W. Seichter, M. Mazik, Eur. J. Org. Chem. 2018,
4317–4330; e) T. M. Jonah, L. Mathivathanan, A. N. Morozov, A. M.
Mebel, R. G. Raptis, K. Kavallieratos, New J. Chem. 2017, 41, 14835–
14838; f) K. H. Ahn, S.-G. Kim, J. Jung, K.-H. Kim, J. Kim, J. Chin, K. Kim,
Chem. Lett. 2000, 29, 170–171; For a review on the recognition of
organic ammonium ions, see: g) A. Späth, B. König, Beilstein J. Org.
Chem. 2010, 6, No.32.
[12] For a unique hydrogen-bonded complex formed between a triethylben-
zene derivative and hydronium and hydroxide ions, see: M. Stapf, W.
Seichter, M. Mazik, Chem. Eur. J. 2015, 21, 6350–6354.
[13] For earlier examples of artificial receptors consisting of a triethylben-
zene-based scaffold, see: a) A. Metzger, V. M. Lynch, E. V. Anslyn, Angew.
Chem. Int. Ed. 1997, 36, 862–865; Angew. Chem. 1997, 109, 911–914; For
a review on 1,3,5-substituted 2,4,6-triethylbenzene derivatives, see:
b) G. Hennrich, E. V. Anslyn, Chem. Eur. J. 2002, 8, 2219–2224.
[14] For examples of macrocyclic carbohydrate receptors reported by our
group, see: a) F. Amrhein, J. Lippe, M. Mazik, Org. Biomol. Chem. 2016,
14, 10648–10659; b) J. Lippe, M. Mazik, J. Org. Chem. 2015, 80, 1427–
1439; c) J. Lippe, M. Mazik, J. Org. Chem. 2013, 78, 9013–9020.
[15] For examples of acyclic carbohydrate receptors consisting of a
biphenyl-, diphenylmethane- or dimesitylmethane-based scaffold, see:
a) M. Mazik, A. König, J. Org. Chem. 2006, 71, 7854–7857; b) M. Mazik,
A. C. Buthe, Org. Biomol. Chem. 2009, 7, 2063–2071; c) N. Koch, J.-R.
Rosien, M. Mazik, Tetrahedron 2014, 70, 8758–8767.
[16] V. Marks, H. E. Gottlieb, A. Melman, G. Byk, S. Cohen, S. E. Biali, J. Org.
Chem. 2001, 66, 6711–6718.
[17] For other 2,4,7-trisubstituted fluorenes containing imidazolyl groups,
see: D. Kumar, K. R. J. Thomas, Y.-L. Chen, Y.-C. Jou, J.-H. Jou, Tetrahedron
2013, 69, 2594–2602.
[18] J. M. Khurana, S. Chauhan, G. Bansal, Monatsh. Chem. 2004, 135, 83–87.
[19] N. Kornblum, J. W. Powers, G. J. Anderson, W. J. Jones, H. O. Larson, O.
Levand, W. M. Weaver, J. Am. Chem. Soc. 1957, 79, 6562.
[20] H. R. Ing, R. H. F. Manske, J. Chem. Soc. 1926, 129, 2348–2351.
[21] For a review, see: V. Martí-Centelles, M. D. Pandey, M. I. Burguete, S. V.
Luis, Chem. Rev. 2015, 115, 8736–8834.
[22] a) T. Shinmyozu, N. Shibakawa, K. Sugimoto, H. Sakane, H. Takemura, K.
Sako, T. Inazu, Synthesis 1993, 1257–1260; b) P. Rajakumar, R. Padma-
nabhan, Tetrahedron 2011, 67, 9669–9679; c) Y.-H. Chang, Y.-J. Lee, C.-C.
Lai, Y.-H. Liu, S.-M. Peng, S.-H. Chiu, Org. Lett. 2018, 20, 2416–2419.
[23] S. Yao, K. D. Belfield, J. Org. Chem. 2005, 70, 5126–5132.
[24] For examples of other fluorenophanes, see: a) P. Rajakumar, R.
Kanagalatha, Tetrahedron Lett. 2007, 2761–2764; b) P. Rajakumar, R.
Anandhan, Synth. Commun. 2013, 43, 882–892.
[25] B. Kenda, Y. Quesnei, A. Ates, P. Michel, L. Turet, J. Mercifer, Patent
WO2006128692 A2, 2006.
Manuscript received: September 13, 2020




1213ChemistryOpen 2020, 9, 1202–1213 www.chemistryopen.org © 2020 The Authors. Published by Wiley-VCH GmbH
Wiley VCH Mittwoch, 25.11.2020
2011 / 184553 [S. 1213/1213] 1
